Distribution of total net revenues

SEK million

2019

Apr-Jun

2018

Apr-Jun

2019

Jan-Jun

2018

Jan-Jun

12 mth

Jul 2018-
Jun 2019

12 mth

Jul 2017-

Jun 2018

Zubsolv® US

184.4

158.4

346.1

289.5

678.2

537.1

Zubsolv - ex US

-

30.8

-

30.8

5.4

36.4

Zubsolv – total

184.4

189.2

346.1

320.3

683.6

573.5

Abstral® royalties

13.1

11.9

24.0

17.7

125.1

112.5

Edluar® royalties

2.4

-1.4

4.2

1.4

9.4

10.7

OX-MPI

1.3

-

1.3

-

1.3

-

Total

201.2

199.7

375.5

339.4

819.3

696.7

 

Key figures

SEK m, unless otherwise stated

2019

Apr-Jun

2018

Apr-Jun

2019

Jan-Jun

2018

Jan-Jun

12 mth

Jul 2018-

Jun2019

12 mth

Jul 2017-
Jun 2018

Net revenues

201.2

199.7

375.5

339.4

819.2

696.7

whereof Zubsolv® US net revenues

184.4

158.4

346.1

289.5

678.2

537.1

Cost of goods sold

-31.3

-37.6

-56.6

-86.0

-142.4

-168.4

Operating expenses

-117.1

-116.7

-265.1

-229.9

-550.8

-433.7

EBIT

52.8

45.4

53.8

23.5

126.0

94.5

EBIT margin, %

26.2

22.7

14.3

6.9

15.4

13.6

US EBIT

87.5

55.5

159.4

80.8

276.7

132.4

US EBIT margin, %

47.4

35.0

46.1

27.9

40.8

24.6

EBITDA

60.4

50.6

72.3

33.7

155.0

115.2

Earnings per share, before dilution, SEK

1.54

1.45

1.93

0.70

5.1

2.29

Earnings per share, after dilution, SEK

1.51

1.45

1.90

0.70

5.0

2.28

Cash flow from operating activities

46.1

39.0

97.1

144.9

193.3

214.6

Cash and cash equivalents

697.0

494.8

697.0

494.8

697.0

494.8

Cash flow

SEK million

2019

Apr-Jun

2018

Apr-Jun

2019

Jan-Jun

2018

Jan-Jun

2018

Jan-Dec

Depreciation/amortization and impairment

7.6

5.2

18.5

10.3

20.8

Change in provisions

12.1

27.5

24.6

84.7

45.6

Share based payments

1.3

0.4

4.4

1.5

2.1

Exchange rate income and expenses

0.1

-3.1

-3.4

-5.8

-6.5

Total

21.2

30.0

44.1

90.7

61.9